Myriad Genetics (NASDAQ:MYGN) PT Raised to $31.00 at The Goldman Sachs Group

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by research analysts at The Goldman Sachs Group from $28.00 to $31.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of […]

Related Keywords

Canada ,United States ,Piper Sandler ,Us Bancorp ,Wolfe Research ,Proshare Advisors ,Nasdaq ,Pricet Rowe Associates Inc ,Genetics Inc ,Royal Bank ,Goldman Sachs Group ,Ameritas Investment Partners Inc ,Wells Fargo Company ,Myriad Genetics ,Get Free Report ,Investment Partners ,Share Advisors ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Myriad Genetics Daily ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Boost Price Target ,The Goldman Sachs Group Inc ,